Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry
about
Urine Aquaporin-2: A Promising Marker of Response to the Arginine Vasopressin Type-2 Antagonist, Tolvaptan in Patients with Congestive Heart FailureHyponatremia Associated with Heart Failure: Pathological Role of Vasopressin-Dependent Impaired Water ExcretionVasopressin Receptor Antagonists for the Correction of Hyponatremia in Chronic Heart Failure: An Underutilized Therapeutic Option in Current Clinical Practice?Mild Chronic Hyponatremia in the Ambulatory Setting: Significance and ManagementAcute Heart Failure Registry: Risk Assessment Model in Decompensated Heart FailureDoes Accidental Overcorrection of Symptomatic Hyponatremia in Chronic Heart Failure Require Specific Therapeutic Adjustments for Preventing Central Pontine Myelinolysis?Factors associated with long-term mortality after Fontan procedures: a systematic review.Physiopathology, clinical diagnosis, and treatment of hyponatremia.Hyponatremia, hypernatremia, and mortality in patients with chronic kidney disease with and without congestive heart failure.Hyponatremia and congestive heart failure: a marker of increased mortality and a target for therapy.Vasopressin antagonists for patients with acute heart failure: interpreting new clinical and translational data.Prevalence and Prognostic Significance of Hyponatremia in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Data from the Akershus Cardiac Examination (ACE) 2 Study.Hyponatremia and hospital outcomes among patients with pneumonia: a retrospective cohort studyRepresentativeness of a national heart failure quality-of-care registry: comparison of OPTIMIZE-HF and non-OPTIMIZE-HF Medicare patients.Rationale and design of the treatment of hyponatremia based on lixivaptan in NYHA class III/IV cardiac patient evaluation (THE BALANCE) study.Preoperative serum albumin levels predict 1-year postoperative survival of patients undergoing heart transplantation.New aspects in the pathogenesis, prevention, and treatment of hyponatremic encephalopathy in childrenTolvaptan.Renal and anti-aldosterone actions of vasopressin-2 receptor antagonism and B-type natriuretic peptide in experimental heart failure.Hyponatremia: A practical approach.Prognostic importance of hyponatremia in patients with acute pulmonary embolism.Clinical practice guideline on diagnosis and treatment of hyponatraemia.Prognostic significance of a multimarker strategy of biomarkers in acute heart failure.Long-term effects and prognosis in acute heart failure treated with tolvaptan: the AVCMA trialAcute heart failure volume control multicenter randomized (AVCMA) trial: comparison of tolvaptan and carperitidePredictors of low cardiac output in decompensated severe heart failure.Tolvaptan, hyponatremia, and heart failure.Lower serum sodium level predicts higher risk of infection-related hospitalization in maintenance hemodialysis patients: an observational cohort study.Moderate hyponatremia is associated with increased risk of mortality: evidence from a meta-analysisHyponatraemia in Emergency Medical Admissions-Outcomes and Costs.Current treatment practice and outcomes. Report of the hyponatremia registry.Prognostic value of hyponatremia in heart failure patients: an analysis of the Clinical Characteristics and Outcomes in the Relation with Serum Sodium Level in Asian Patients Hospitalized for Heart Failure (COAST) study.Predictors of medication nonadherence differ among black and white patients with heart failure.Pulmonary hypertension, right ventricular failure, and kidney: different from left ventricular failure?Plasma bioactive adrenomedullin as a prognostic biomarker in acute heart failureHyponatremia predicts right heart failure and poor survival in pulmonary arterial hypertension.A cross-sectional study of hyponatraemia among elderly patients with heart failure in Uganda.Heart failure in North America.Transient Hyponatremia During Hospitalization for Acute Heart Failure.Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected].
P2860
Q26771172-1D97BE72-E3BD-4044-A64B-202913A23178Q26799518-105519C8-3FFA-4184-97DD-74BD98B30247Q28071921-EF1ED247-7F55-4B98-B706-0B72C3DB3D7DQ28082901-4D977DE1-9981-44FB-A044-AD314066E724Q30100975-EE3B1DA2-1DB2-4D74-8D29-0D0B09C23AA4Q30235394-89B6A5DE-083C-4E87-9E98-4016E150BE36Q30239813-CB2BD681-CC83-4C73-8174-54BEDE08E4E2Q30240732-595F52D1-1947-444B-9C1F-78164C23F69CQ30422457-B6652BF0-35D9-4119-807C-A76110E49C4EQ30432267-85652F43-EA33-420A-9873-2D7BCBD9D534Q30717243-417385D2-7460-411A-AE88-4325A7B62F57Q31121896-ECB0471E-DCDA-4FB3-AC33-12945CE70B25Q33360986-6A433FF0-B390-4C90-826C-C133373A61EFQ33572449-052EA2CF-1847-4DC7-AA31-294485C79608Q33712822-31DE0578-86AF-4518-ABDC-DEC24C319611Q33818484-675CE515-2F09-4EFF-B19C-1BD4AFFBE403Q33866957-80E0D991-BF14-4697-9D99-6EA405A7F5E7Q34052281-42FCEF50-A65D-4EB5-8B10-61C5A3B1841AQ34305164-A0365B99-05AF-4EA8-8899-B11BB56BF7DAQ34319649-D72BC49D-E769-48BD-963E-DD59FBE40D03Q34402419-4FE053D2-F8A8-4744-B908-430FB1A461E2Q34406779-56894003-2F43-45D9-8DDE-75C77A054C19Q34479808-8869FBEE-A287-4091-8808-980C70C02947Q34570220-E7AE6800-454C-486F-BE3E-CD136DDFD4DFQ34643664-0801D1C2-2AD5-489F-8062-5716FC7470CEQ34691554-AE6F6DBC-1708-422C-B564-A7092E25882AQ35026759-DDC1477D-2235-475E-91AB-71C42251FA80Q35071916-E7FD00E6-DBEC-47CF-B0AB-1D3DAC23D0A3Q35075197-FA7B6AD7-1ED9-45DD-AB19-852CE984712BQ35750541-E0256C00-C08B-4089-BDB7-EC5C307DDA5BQ35814224-A85F3F26-F745-4E1B-9EC3-9061644CAB8BQ35834936-20EDAA9C-493B-4698-BD35-30CEC92E1579Q35855340-E4A17276-DB70-4493-960C-E83B430EEFA9Q36063303-BAF93C64-0AC1-4AF5-810E-F8E4F3826971Q36578779-5F1686C9-E99C-4623-92F4-57354C4CF8C4Q36718655-55CC8808-5950-41C9-B48F-A8EC882052C0Q36920108-0DC77D0E-480B-4565-8A09-9B4DF139C92AQ36928519-E2895529-D834-4B8D-8714-009F752F9EB0Q36932571-506A17B5-E017-4A14-B816-1BBCF13D930EQ36962261-759609CC-E412-4B90-85D9-B6CE3D61FD11
P2860
Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry
description
article
@en
im April 2007 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована у квітні 2007
@uk
name
Relationship between admission ...... from the OPTIMIZE-HF registry
@en
Relationship between admission ...... from the OPTIMIZE-HF registry
@nl
type
label
Relationship between admission ...... from the OPTIMIZE-HF registry
@en
Relationship between admission ...... from the OPTIMIZE-HF registry
@nl
prefLabel
Relationship between admission ...... from the OPTIMIZE-HF registry
@en
Relationship between admission ...... from the OPTIMIZE-HF registry
@nl
P2093
P356
P1476
Relationship between admission ...... from the OPTIMIZE-HF registry
@en
P2093
B. H. Greenberg
C. M. O'Connor
G. C. Fonarow
M. Gheorghiade
N. M. Albert
W. Gattis Stough
W. T. Abraham
P304
P356
10.1093/EURHEARTJ/EHL542
P50
P577
2007-04-02T00:00:00Z